Retrospective Study on Prognostic Factors for Post-void Residual Volume Following Intravesical Injection of Botulinum Toxin for Severe Overactive Bladder: A Urodynamic Investigation

Severely overactive bladder patients who visited Yokosuka Women's Urology and Urology Clinic (abbreviated as Yokosuka Women's Urology) in Japan received intravesical injection treatment of botulinum toxin (abbreviated as BOTOX bladder treatment) covered by national health insurance, in accordance with Japanese guidelines. During this treatment, necessary and sufficient therapy and examinations are conducted following the criteria set by the country and guidelines provided by the Japanese Urological Association. The analysis of these examination data is of utmost importance. Currently, studies on predictive factors for post-treatment effects and side effects in this treatment are based on data sets involving American subjects, calculated by researchers from a university in Taiwan. There have been no research reports from facilities in other countries. Therefore, this retrospective trial aims to investigate the predictive factors in an Asian population under the same conditions, conducted at medical facilities in Japan. It should be noted that post-void residual refers to the condition where 200ml or more of urine remains in the bladder immediately after voiding, as defined by the International Continence Society.